Schwab Charles Investment Management Inc. lifted its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 447,363 shares of the specialty pharmaceutical company’s stock after purchasing an additional 22,488 shares during the period. Schwab Charles Investment Management Inc. owned about 1.26% of AMAG Pharmaceuticals worth $5,928,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hartford Investment Management Co. acquired a new stake in shares of AMAG Pharmaceuticals during the third quarter worth about $186,000. Cubist Systematic Strategies LLC acquired a new stake in shares of AMAG Pharmaceuticals during the third quarter worth about $197,000. 361 Capital LLC acquired a new stake in shares of AMAG Pharmaceuticals during the third quarter worth about $197,000. Aperio Group LLC acquired a new stake in shares of AMAG Pharmaceuticals during the third quarter worth about $198,000. Finally, Municipal Employees Retirement System of Michigan increased its position in shares of AMAG Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after purchasing an additional 4,870 shares in the last quarter.
AMAG Pharmaceuticals, Inc. (AMAG) opened at $20.45 on Tuesday. The company has a current ratio of 1.74, a quick ratio of 1.60 and a debt-to-equity ratio of 0.93. AMAG Pharmaceuticals, Inc. has a twelve month low of $11.93 and a twelve month high of $24.85. The stock has a market capitalization of $698.82, a PE ratio of 97.62 and a beta of 0.28.
AMAG has been the topic of a number of research analyst reports. Jefferies Group cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the stock from $21.00 to $20.00 in a research report on Monday, March 5th. B. Riley reiterated a “hold” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Tuesday, January 16th. Cantor Fitzgerald reissued a “hold” rating and set a $17.00 price target on shares of AMAG Pharmaceuticals in a report on Wednesday, February 14th. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Finally, ValuEngine raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $23.27.
TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/amag-pharmaceuticals-inc-amag-shares-bought-by-schwab-charles-investment-management-inc.html.
AMAG Pharmaceuticals Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.